Skip to main content
SpringerLink
Log in

Antiestrogen Regulation of erbB2 Expression in Human Breast Cancer Cells

  • Chapter
Tamoxifen

  • 103 Accesses

Abstract

The erbB2 protein is supposed to have important functions as a growth factor receptor during growth and differentiation as well as in normal function of the mammary epithelium. It can be activated to a transforming oncogene and in human breast cancer, the amplification and/or overexpression of erbB2 gene is associated with aggressive growth of the tumor and poor prognosis of the patient. The expression of erbB2 is regulated by estrogen and the antiestrogens Tamoxifen and Toremifene which are both used in the treatment of breast cancer. The knowledge of the role and mechanisms of the anti estrogen regulation of this important growth factor receptor and potential oncogene would provide important information of the biology and therapeutic possibilities of human breast cancer.

“Genes are thicker than water. ”

(Meredith Small)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alper Ö, Yamaguchi K, Hitomi J, Honda S, Matsiushima T, Abe K (1991): The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Cell Growth Different 1:591–599

    Google Scholar 

  • Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R (1992): A ligand for the erbB-2 oncogene product (gp 30) induces differentiation of human breast cancer cells. Cell Growth Different 3:401–411

    CAS  Google Scholar 

  • Bargmann CI, Weinberg RA (1988): Increased tyrosine kinase activity associated with the protein encoded by the activatedneu oncogene. Proc Natl Acad Sci USA 85:5394–5398

    Article  PubMed  CAS  Google Scholar 

  • Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992): Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 244:85–95

    Article  Google Scholar 

  • Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Sigurdsson H (1991): ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137–143

    PubMed  CAS  Google Scholar 

  • Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H (1994): ERBB2 amplification is associated with tamoxifen resistence in steroid receptor positive breast cancer. Cancer Lett 81:137–144

    Article  PubMed  CAS  Google Scholar 

  • Bouchard L, Lamarre L, Tremblay PL, Jolicoeur P (1989): Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931–936

    Article  PubMed  CAS  Google Scholar 

  • Breuer B, Luo J-C, DeVivo I, Pincus M, Tatum AH, Daucher J, Minick R, Osborne M, Miller D, Nowak E, Code H, Carney WP, Brandt-Rauf PW: (1993) Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer. Med Sci Res 21:383–384

    Google Scholar 

  • Carraway III KL, Cantley LC (1994): A new aquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5–8

    Article  PubMed  CAS  Google Scholar 

  • Chen Y, Gill GN (1994): Positive and negative regulatory elements in the human erbB-2 gene promoter. Oncogene 9:2269–2276

    PubMed  CAS  Google Scholar 

  • Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL (1992): Correlation of HER2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84:1279–1282

    Article  PubMed  CAS  Google Scholar 

  • Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M (1990): Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001–1006

    PubMed  CAS  Google Scholar 

  • Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987): erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182

    Article  PubMed  Google Scholar 

  • Dougall WC, Qian X, Peterson NC, Miller M, Samanta A, Greene MI (1994): The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109–2123

    PubMed  CAS  Google Scholar 

  • Gasparini G, Pozza F, Harris AL (1993): Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219

    Article  PubMed  CAS  Google Scholar 

  • Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG (1991): c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434–438

    Article  PubMed  CAS  Google Scholar 

  • Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992): Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582

    Article  PubMed  CAS  Google Scholar 

  • Hollywood DP, Hurst HC (1993): A novel transcription factor, OB2–1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12:2369–2375

    PubMed  CAS  Google Scholar 

  • Hudson LG, Ertl AP, Gill GN (1990): Structure and inducible regulation of the human c-erbB2/neu promoter. J Biol Chem 265:4389–4393

    PubMed  CAS  Google Scholar 

  • Hudziak RM, Schlessinger J, Ullrich A (1987): Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159–7163

    Article  PubMed  CAS  Google Scholar 

  • Hung M-C, Schechter AL, Chevray P-YM, Stern DF, Weinberg RA (1986): Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 83:261–264

    Article  PubMed  CAS  Google Scholar 

  • Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P (1994): Elevated erbB2 oncoprotein levels in pre-operative and follow-up serum samples define breast cancer patients with aggressive disease course. Cancer 3:652–658

    Article  Google Scholar 

  • Johnston SRD, McLennan KA, Salter J, Sacks NM, McKinna JA, Baum M, Smith IE, Dowsett M (1993): Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo. The Breast 2:93–99

    Google Scholar 

  • Jordan VC, Murphy CS (1990): Endocrine pharmacology of antiestrogens as antitumor agents. Endoer Rev 11:578–610

    Article  CAS  Google Scholar 

  • Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Piippo I, Sundquist H, Södervall M, Toivola R (1986): A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 17:103–108

    Article  PubMed  CAS  Google Scholar 

  • Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH and Isola JJ (1993): Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650–655

    Article  Google Scholar 

  • Kallioniemi O-P, Kallioniemi A, Kurisu W, Thor A, Chen L-C, Smith HS, Waldman, FM, Pinkel D, Gray, JW (1992): ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321–5325

    Article  PubMed  CAS  Google Scholar 

  • Kangas L, Nieminen A-L, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perila M, Södervall M, Toivola R (1986): A new triphenylethylene compound, Fc-1157a. II. Antitumor effect. Cancer Chemother Pharmacol 17:109–113

    Article  PubMed  CAS  Google Scholar 

  • Koskinen P, Lehväslaiho H, MacDonald-Bravo H, Alitalo K, Bravo R (1990): Similar early responses to ligand-activated EGFR andneu tyrosine kinases in NIH3T3 cells. Oncogene 5:615–618

    PubMed  CAS  Google Scholar 

  • Kraus MH, Fedi P, Starks V, Muraro R and Aaronson SA (1993): Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90:2900–2904

    Article  PubMed  CAS  Google Scholar 

  • Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE (1991): An antigen immunologically related to the extracellular domain of gp185 in shed from nude mouse tumors over-expressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 51:2593–2598

    PubMed  CAS  Google Scholar 

  • Lehväslaiho H, Lehtola L, Sistonen L, Alitalo KA (1989): Chimeric EGF-R/neu proto-oncogene allows to regulate neu tyrosine kinase and cell transformation. EMBO J 8:159–166

    PubMed  Google Scholar 

  • Leitzel K, Teramoto Y, Sampson EL, Wallingford GA, Weaver S, Domero L, Harvey H, Lipton A (1991): Elevatedc-erbB-2 levels in the serum and tumor extracts of breast cancer patients. Proc Am Assoc Cancer Res 32:997–1005

    Google Scholar 

  • Lin YJ and Clinton GM (1991): A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6:639–643

    PubMed  CAS  Google Scholar 

  • Marchionni MA, Goodearl ADJ, Che MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kovayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty N, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D (1993): Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312–318

    Article  PubMed  CAS  Google Scholar 

  • Marte BM, Jeschke M, Graus-Porta D, Taveraa D, Hofer P, Groner B, Yarden Y, Hynes NE (1995): Neu differentiation factor/heregulin modulates growth and differentiation of HC 11 mammary epithelial cells. Mol Endocrinol 9:14–23

    Article  PubMed  CAS  Google Scholar 

  • Meyer D and Birchmeier C (1994): Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc Natl Acad Sci USA 91:1064–1068

    Article  PubMed  CAS  Google Scholar 

  • Müller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988): Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115

    Article  PubMed  Google Scholar 

  • Pasleau F, Grooteclaes M, Gol-Winkler R (1993): Expression of the c-erbB2 gene in the Bt-474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 8:849–85

    PubMed  CAS  Google Scholar 

  • Peles E and Yarden Y (1993): Neu and its ligands: from an oncogene to neural factors. BioEssays 15:815–824

    CAS  Google Scholar 

  • Perren TJ (1991): c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328–332

    Article  PubMed  CAS  Google Scholar 

  • Philips A, Chalbos D, Rochefort H (1993): Estradiol increases and antiestrogens antagonize the growth factor-induced Activator Protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103–14108

    PubMed  CAS  Google Scholar 

  • Pierce JH, Arnheim P, DiMarco E, Artrip J, Kraus MH, Lonardo F (1991): Oncogenic potential of erbB2 in human mammary epithelial cells. Oncogene 6:1189–1194

    PubMed  CAS  Google Scholar 

  • Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M (1993): Ligand-specific activation of HER-4/p180Berb B4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746–1750

    Article  PubMed  CAS  Google Scholar 

  • Prigent SA, Lemoine NR (1992): The type 1 (EGFR-related) family of growth factor receptors and their ligands. Progr Growth Factor Res 4:1–24

    Article  CAS  Google Scholar 

  • Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS (1990): Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947–3951

    PubMed  CAS  Google Scholar 

  • Rüssel KS, Hung M-C (1992): Transcriptional repression of the neu proto-oncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624–6629

    Google Scholar 

  • Scott GK, Robels R, Park JW, Montgomery PA, Daniel J, Holmes WE, Keller GA, Li W-L, Fendly BM, Wood WI, Shepard M, Benz CC (1993): A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13:2247–2257

    PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987): Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989): Studies of the HER-2Ineu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  Google Scholar 

  • Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, D’Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B (1994): The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13:6:1331–1340

    PubMed  CAS  Google Scholar 

  • Stern DF, Kamps MP, Cao H (1988): Oncogenic activation of pp180neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969–3973

    PubMed  CAS  Google Scholar 

  • Taverna D, Groner B, Hynes NE (1991): Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Cell Growth Different 2:145–154

    CAS  Google Scholar 

  • Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE (1994): erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56:522–528

    Google Scholar 

  • Ullrich A, Schlessinger J (1990): Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212

    Article  PubMed  CAS  Google Scholar 

  • Van de Vijver MJ, Nusse R (1991): The molecular biology of breast cancer. Biochim Biophys Acta 1072:35–50

    Google Scholar 

  • Wärri AM, Laine AM, Majasuo KE, Alitalo KK, Härkonen PL (1991): Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR 75–1 human breast cancer cells in vitro and in nude mice. Int J Cancer 49:616–623

    Article  PubMed  Google Scholar 

  • Wärri AM (1993): Toremifene-induced regression in breast cancer. Cellular and molecular mechanisms. Academic Dissertation. University of Turku, Turku, Finland

    Google Scholar 

  • Wärri AM, Isola JJ, Härkonen PL (1994): Estrogen and antiestrogen regulation of amplified erbB2 gene expression in human cancer cells. In: Hormonal Carcinogenesis, 2nd Ed., J.J. Li, S. Nandi and S.A. Li (Eds) Springer-Verlag

    Google Scholar 

  • Wärri AM, Isola JJ, Härkonen PL (1995): Antiestrogen stimulation of erbB2 ectodomain shedding from BT-474 human breast cancer cells with erbB2 gene amplification. Eur J Cancer (In Press)

    Google Scholar 

  • Webb P, Lopez GN, Uht RM, Kushner PJ (1995): Tamoxifen activation of the estrogen receptor/AP-i pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443–456

    Article  PubMed  CAS  Google Scholar 

  • Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW (1992): Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118–121

    Article  PubMed  CAS  Google Scholar 

  • Zabrecky JR, Lam T, McKenzie SJ, Carney, W (1991): The extracellular domain of p185neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716–1720

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anni M. Wärri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pirkko L. Härkönen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 89 Rameau Drive, Toronto, Ontario, M2H 1T6, Canada

    John A. Kellen

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Birkhäuser Boston

About this chapter

Cite this chapter

Wärri, A.M., Härkönen, P.L. (1996). Antiestrogen Regulation of erbB2 Expression in Human Breast Cancer Cells. In: Kellen, J.A. (eds) Tamoxifen. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4092-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4092-1_15

  • Publisher Name: Birkhäuser Boston

  • Print ISBN: 978-1-4612-8648-6

  • Online ISBN: 978-1-4612-4092-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation